There are 3161 resources available
452MO - Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial
Presenter: Estela Pineda
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
1966MO - EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Presenter: Thomas Powles
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
453MO - A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast
1967MO - Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
Presenter: Matthew Galsky
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1965MO, 1966MO and 1967MO
Presenter: Aristotelis Bamias
Session: Mini oral session: GU tumours, non-prostate
Resources:
Slides
Webcast
Invited Discussant 451MO, 452MO and 453MO
Presenter: Roger Stupp
Session: Mini oral session: CNS tumours
Resources:
Slides
Webcast
Welcome and introduction
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers Squibb - A decade of anti—PD-1—based therapies for melanoma: looking beyond the curves
Resources:
Webcast
Welcome and Introduction
Presenter: Laurence Albiges
Session: Ipsen - Kidney cancer puzzles – from insights to progress
Resources:
Webcast
Welcome and introduction
Presenter: Joyce O'Shaughnessy
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Webcast
Welcome and Introduction
Presenter: Toni Choueiri
Session: Eisai Inc. - Evolving Treatment Sequence for Renal Cell Carcinoma
Resources:
Webcast